FDMT 4D Molecular Therapeutics, Inc.

NASDAQ
$12.19

4D Molecular Therapeutics, Inc. (FDMT) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $1.04 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.8% since its last earnings release on August 13, 2026.

4D Molecular Therapeutics Reported In-line with Estimates
Thursday, August 13, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($1.04)
Rev est $1.61M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $12.19

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About 4D Molecular Therapeutics, Inc.

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies.

Sector

Healthcare

Industry

Biotechnology